Rheumatologists must navigate patients through complex world of biosimilars

News that a second biosimilar has now been ‘a’ flagged in the absence of an adequate pharmacovigilance program means it is now down to rheumatologists to help their patients navigate the increasingly complex world of biosimilars, the ARA says. On Friday the PBAC announced that they had decided to ‘a’ flag Brenzys and its originator ...

Already a member?

Login to keep reading.

© 2021 the limbic